Technology Considerations for production of Antibodies and Antibody-Drug Conjugates in Cancer TherapyAuthor(s): Anna Dobrev
The cornerstone for the therapeutic antibody field’s explosive growth and development is the capacity of monoclonal antibodies to bind to a target antigen with high specificity and either neutralise or boost its activity. Traditional immunoglobulin antibodies have recently undergone additional engineering for improved efficacy and safety, and technological advances in the field have made it possible to design and produce engineered antibodies that can mediate therapeutic functions that were previously not possible by conventional antibody formats. Bispecific antibodies and antibody-drug conjugates, each with several approved medications and dozens more in the clinical research stage, serve as examples of this more recent generation of therapeutic antibody forms. The technological underpinnings and difficulties of bispecific antibodies and antibody-drug conjugates are covered in this review, with a focus on clinically validated formats and recent advancements in the field, many of which are anticipated to significantly expand the current therapeutic arsenal against cancer and other diseases with unmet medical needs [1-5].